Immunomedics (IMMU) Earning Somewhat Favorable Press Coverage, Accern Reports
Media stories about Immunomedics (NASDAQ:IMMU) have been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Immunomedics earned a news impact score of 0.10 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.9875380560653 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the headlines that may have effected Accern Sentiment’s rankings:
- Immunomedics (IMMU) & Its Peers Head to Head Review (americanbankingnews.com)
- Immunomedics, Inc. (NASDAQ: IMMU) – Hot Stock’s Highlights – Alpha Beta Stock (alphabetastock.com)
- Immunomedics Inc (NASDAQ:IMMU) Just Validated Our Bullish Thesis – Insider Financial (insiderfinancial.com)
- Surprising Stock- Immunomedics, Inc. (NASDAQ:IMMU) – The Stock Street (press release) (thestreetpoint.com)
- Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : December 8, 2017 (finance.yahoo.com)
Shares of Immunomedics (IMMU) opened at $12.44 on Monday. The company has a current ratio of 0.74, a quick ratio of 0.74 and a debt-to-equity ratio of -0.29. Immunomedics has a 1 year low of $3.30 and a 1 year high of $14.48.
In other Immunomedics news, Director Venbio Select Advisor Llc acquired 1,150,000 shares of the business’s stock in a transaction dated Tuesday, November 14th. The shares were acquired at an average price of $10.39 per share, with a total value of $11,948,500.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Brian A. Markison sold 8,390 shares of the business’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $11.89, for a total transaction of $99,757.10. Following the completion of the sale, the director now directly owns 99,178 shares in the company, valued at approximately $1,179,226.42. The disclosure for this sale can be found here. Insiders own 6.60% of the company’s stock.
Immunomedics Company Profile
Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
Receive News & Stock Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related stocks with our FREE daily email newsletter.